GlassScriptPhysician profile
Catherine M Raff
NPI 1578567004
$7,285.65
in general payments reported to CMS, 2019-2025
31 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,060 · 2022: $2,350 · 2023: $1,148 · 2024: $1,488 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,730.91 | 2021-2025 | |
| Novo Nordisk INC | $645.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $466.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $458.92 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $422.48 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $421.19 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Inogen, INC. | $189.60 | 2022-2025 | Inogen At Home Stationary Concentrator |
| Mylan Specialty L.P. | $157.77 | 2021-2024 | Yupelri |
| Amgen INC. | $145.70 | 2021-2024 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.61 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $137.91 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $137.58 | 2022-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $133.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $125.73 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.80 | 2021-2023 | Synjardy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $101.09 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $100.27 | 2024-2025 | Gemtesa |
| Pfizer INC. | $95.90 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.78 | 2024-2025 | |
| Lundbeck LLC | $69.34 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $64.39 | 2024-2025 | Auvelity |
| Nestle Healthcare Nutrition INC. | $61.24 | 2021-2023 | |
| Amarin Pharma, INC. | $57.44 | 2021 | |
| Vanda Pharmaceuticals INC. | $52.61 | 2024-2025 | Hetlioz, Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $50.96 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.99 | 2024-2025 | Caplyta |
| Ardelyx, INC. | $20.75 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $18.98 | 2021 | |
| Intra-Sana Laboratories | $18.27 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Viatris Specialty LLC | $17.64 | 2025 | Yupelri |
| Eisai INC. | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Raff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.